News

Bread Financial Secures Funding Through New Preferred Stock Offering

Bread Financial Secures Funding Through New Preferred Stock Offering

Exciting Development in Funding for Bread Financial

Bread Financial Holdings, Inc. (NYSE: BFH) has announced an important milestone in its corporate journey with the pricing of its underwritten public offering of depositary shares. Each of these shares represents a 1/40th interest in a share of its Non-Cumulative Perpetual Preferred Stock, Series A, with a par value of $0.01 per share. This offering is poised to provide Bread Financial with robust capital, enhancing its operational capabilities.

Details of the Offering

The company's offering comes with a liquidation preference of $25 per depositary share, amounting to $1,000 per share of the Series A Preferred Stock. This strategic financial move reflects Bread Financial’s commitment to strengthening its financial position and expanding its service capabilities across the market.

Expected Completion and Uses of Proceeds

Closing of the offering is scheduled for November 25, 2025, provided all customary conditions are met. This offering is expected to generate around $72.6 million in net proceeds for the company, after accounting for underwriting discounts and expenses associated with the offering.

Targets for Investment

The net proceeds from this initiative will support a variety of corporate purposes. These may include lending or contributing capital to one of its subsidiary banks, Comenity Capital Bank, and conducting share repurchases, which showcases the company’s strategic direction in utilizing funds effectively.

Role of Leading Financial Institutions

Notably, Wells Fargo Securities, LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and RBC Capital Markets, LLC are serving as joint bookrunners for this significant offering. Their expertise will assist in managing this public offering efficiently and effectively.

About Bread Financial

Bread Financial (NYSE: BFH) distinguishes itself as a tech-savvy financial services provider, delivering personalized payment, lending, and saving solutions. The company serves millions of consumers across the U.S., implementing innovative financial products that empower customers to achieve their personal and financial goals.

Commitment to Consumer Empowerment

Bread Financial’s payment solutions, which include general purpose credit cards and various savings offerings, are aimed at helping customers enjoy a better financial life. The company collaborates with major brands in travel, health, beauty, jewelry, and apparel, leveraging its co-brand and private label credit cards to create value for consumers.

How to Access the Offering

The offering is part of an effective registration statement previously filed with the Securities and Exchange Commission (SEC). Investors looking to obtain a final prospectus supplement, along with an accompanying prospectus, will find these documents posted on the SEC's website, aimed at providing transparency and accessibility to potential investors.

Investor Relations Contacts

For further inquiries, investors can reach out directly to the Bread Financial Investor Relations team. Brian Vereb and Susan Haugen are available for any questions regarding financial performance or this offering. Additionally, Rachel Stultz is reachable for media relations. The direct emails for these contacts are Brian.Vereb@breadfinancial.com and Susan.Haugen@breadfinancial.com.

Frequently Asked Questions

What is the purpose of the offering?

The offering aims to raise capital for general corporate purposes, including support for subsidiary banks and potential share repurchases.

When does the offering close?

The closing of the offering is expected to occur on November 25, 2025, subject to standard conditions.

Who are the bookrunners for the offering?

The joint bookrunners include Wells Fargo Securities, J.P. Morgan Securities, Morgan Stanley, and RBC Capital Markets.

What benefits do the depositary shares offer?

The depositary shares represent a fractional ownership in preferred stock, providing investors with potential dividends and a preference in the event of liquidation.

How can investors learn more about this offering?

Details about the offering, including a prospectus, will be available on the SEC's website and can also be requested from the bookrunners of the offering.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 23

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Therapeutics Gains Confidence with Strategic Developments

Updated Category News Views 60

Piper Sandler's Renewed Confidence in Context Therapeutics Piper Sandler has reiterated an Overweight rating for Context Therapeutics (NASDAQ: CNTX), maintaining a price target of $4.50 for the stock. This endorsement underscores their belief in the company’s potential within the biopharmaceutical sector. Positive Data from Competitors Enhances Expectations This renewed...

Continue Reading
Actinium's ATNM-400: A Promising Frontier in Prostate Cancer Therapy

Updated Category News Views 167

Introduction to ATNM-400's Innovative Approach Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced compelling preclinical data showcasing its innovative treatment, ATNM-400. This first-in-class antibody radioconjugate targets a unique, non-PSMA antigen, revolutionizing prostate cancer therapy. ATNM-400 offers noteworthy therapeutic activity independent of...

Continue Reading
Opportunity Knocks: Ligon's Major Auction Up for Bids

Updated Category News Views 17

Equipment Auction Offers Unique Buying Opportunity Catch this: Ligon Co.'s auction is like finding a needle in a haystack in a world of overpriced equipment. We're talking about a smorgasbord of heavy machinery up for online grabs, and it’s happening until June 17. Auction Highlights: Your Next Business Asset? From telehandlers to trailers, this ain't your everyday yard...

Continue Reading
Selector Enhances Service Delivery with AWS Marketplace Launch

Updated Category News Views 147

Selector Launches on AWS Marketplace for Better Accessibility Selector, a pioneer in AI-driven observability and network intelligence, is transforming how organizations manage their network operations. The company has launched its flagship platform on the Amazon Web Services (AWS) Marketplace, which makes it easier for customers to procure and deploy its powerful AI tools...

Continue Reading
Exploring the Surge in Decentralized Energy Storage Growth

Updated Category News Views 229

Decentralized Energy Storage Market Overview The Decentralized Energy Storage market is gaining remarkable traction, with significant insights indicating a shift towards sustainable energy solutions. Valued at approximately USD 10.88 billion, the market is anticipated to expand to a staggering USD 35.62 billion, exhibiting a compound annual growth rate (CAGR) of 15.98%...

Continue Reading